Upcoming Earnings Overview:
The upcoming earnings report for DexCom, Inc. (DXCM) is scheduled for Wednesday, April 29th. Analysts expect a consensus EPS estimate of 0.47.
Live Analysis:
DexCom, Inc. (DXCM) is currently priced at $60.64, showing a decrease of -77.15 cents (-1.26%) from the previous close at $61.41. The trading volume is $760,742, representing a 17.26% deviation from the average.
Performance Streak:
DXCM has experienced a three-day streak of price decline, with a total decrease of $-2.77 (-4.37%) from a starting price of $63.41.
Earnings Overview:
The latest quarterly earnings for DXCM were reported on Wednesday, February 11th, with a consensus EPS estimate of 0.65.
Cash Flow:
DXCM's cash flow activities show a net change in cash of -$917.8 million, with operating cash flow of $294 million and free cash flow of $192.1 million.
Income Statement:
In the most recent financial period, DXCM reported a net income of $267.3 million, with an EPS of 69 cents and a diluted EPS of 67 cents.
Ratios:
Key financial ratios for DXCM include a net profit margin of 21.22%, return on equity of 9.73%, and a price-to-earnings ratio of 24.
Balance Sheet:
DXCM's balance sheet highlights total assets of $6.34 billion, with total liabilities standing at $3.59 billion, and net debt at $472 million.
This comprehensive overview provides insights into DXCM's current financial status and performance leading up to the upcoming earnings report.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.